This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amgen Announces Appointment Of Robert A. Eckert To Board Of Directors

THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Robert A. Eckert, former chief executive officer at Mattel, Inc., to its Board of Directors. Mr. Eckert will serve on the Audit and Corporate Responsibility and Compliance Committees of the Board. Following the appointment of Mr. Eckert and the previously announced retirement of Kevin W. Sharer from the Board on Dec. 31, 2012, the Board on Jan. 1, 2013, will be comprised of 14 directors, 13 of whom are independent.

"We are pleased to welcome Bob Eckert to the Amgen Board. Bob has significant experience and a superb track record of leading global companies during a long and successful career," said Robert A. Bradway, chief executive officer at Amgen. "His contributions to the Board will guide us as we expand our reach to more patients in more markets and continue creating value for our stockholders."

Robert A. Eckert

Mr. Eckert, 58, currently serves as non-executive Chairman at Mattel, Inc., where he served as Chief Executive Officer from 2000 through 2011. Prior to this role, Mr. Eckert was President and Chief Executive Officer of Kraft Foods, Inc. from 1997 to 2000. Before that, Mr. Eckert served as Group Vice President and President of Kraft's Oscar Mayer foods division. Mr. Eckert currently serves on the Boards of Directors of McDonald's Corporation and Levi Strauss & Co.  Mr. Eckert is on the Dean's Advisory Board of the Kellogg Graduate School of Management and serves on the Eller College of Management National Board of Advisors at the University of Arizona. Mr. Eckert holds a Bachelor of Arts degree from the University of Arizona and an MBA from Northwestern University.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit Follow us on

CONTACT: Amgen, Thousand Oaks Ashleigh Koss, 805-313-6151 (media) Arvind Sood, 805-447-1060 (investors)



Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs